Follow the answer back to its source

Read the result with its limits

STEP 1 enrolled 1,961 adults who had obesity, or overweight with a related condition, and had no diabetes.

Over 68 weeks, semaglutide participants lost an average 14.9% of body weight, compared with 2.4% in the placebo group, whose treatment contained no active medicine.

Both groups had advice about daily habits, such as eating and physical activity, as well as regular visits. The maker Novo Nordisk funded the study.

Ask how that extra help compares with the help you would get.

SURMOUNT-5 compared tirzepatide with semaglutide in 751 adults with obesity who did not have type 2 diabetes.

Average body-weight loss over 72 weeks was 20.2% with tirzepatide and 13.7% with semaglutide.

Participants knew which medicine they received. Eli Lilly, the maker of tirzepatide, ran and funded the study.

These are group averages, rather than a forecast for one person. The figures describe those trials, rather than every care route.

Start with the official records

Use your location during the appointment to choose the medical-board starting point for the relevant state.

Check what the product claim means

Read the label for the actual product

Use the label for the product being discussed, then take unclear points to the prescriber.

Read the payment terms at the source

Medicare is run by the federal agency called CMS.

The prices and federal compounding rules shown here were checked in September 2026. They may change after that date.

Compare an offer’s written terms with the exact product being discussed. A study result does not answer the billing question.